Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Liu, Chun‐Jen; Chuang, Wan‐Long; Lee, Chuan–Mo; Yu, Ming‐Lung; Lu, Sheng–Nan; Wu, Shuo‐Jye; Liao, Li‐Ying; Chen, Chi‐Ling; Kuo, Hsing‐Tao; Chao, You‐Chen; Tung, Shui‐Yi; Yang, Sien–Sing; Liu, Chen–Hua; Su, Wei‐Wen; Lin, Chih–Lin; Jeng, Yung‐Ming; Chen, Pei‐Jer; Chen, Ding‐Shinn

doi:10.1053/j.gastro.2008.10.049

Cited by 192 publications

(189 citation statements)

References 36 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…In patients with HCV genotype 1 infection, the rate of sustained virologic response (SVR) at 24 weeks (SVR24) after the end of combination therapy with peginterferon alfa-2a and ribavirin was 72.2% in coinfected patients versus 77.3% in monoinfected patients; for patients with HCV genotype 2/3 infection, the SVR24 values were 82.8% and 84.0%, respectively. 8 These results suggest that combination therapy is equally effective in patients with HCV monoinfection and in those with chronic HCV/HBV coinfection. In addition, posttreatment hepatitis B surface antigen (HBsAg) seroclearance was observed in 11.2% of 161 coinfected patients.…”

mentioning

confidence: 90%

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Lee

Chen

et al. 2013

Hepatology

View full text Add to dashboard Cite

Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCVmonoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n 5 97) and HBVmonoinfected (n 5 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n 5 64) and monoinfected (n 5 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 6 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1/HBV-coinfected patients and one HCV genotype 2/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group. Conclusion: Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. (HEPATOLOGY 2013;57:2135-2142

show abstract

mentioning

confidence: 90%

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Lee

Chen

et al. 2013

Hepatology

View full text Add to dashboard Cite

show abstract

“…An open-label, comparative, multicenter study conducted in Taiwan has shown recently that PegIFN 2a plus ribavirin is equally effective in patients with HCV monoinfection (SVR: 77% in genotype 1 and 84% in genotype 2/3) and in those with dual chronic HCV/HBV infection and negative for hepatitis B e antigen (HBeAg) (SVR: 72% in genotype 1 and 83% in genotype 2/3). Besides, reactivation of HBV DNA at 6 months after treatment was observed in 36.3% of HBV DNA-negative patients [27]. The results dramatically suggest that SOC regimen in HCV monoinfected patients Dig Dis Sci (2010) 55:3300-3303 3301…”

mentioning

confidence: 83%

Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More?

2010

Dig Dis Sci

View full text Add to dashboard Cite

“…Moreover, a large prospective randomized, controlled, multicenter study by Liu et al [40] evaluated peg-IFN and RBV in HCV/HBV-coinfected patients. High SVR rates (72% and 83% in genotypes 1 and 2/3 respectively) achieved.…”

Section: Evolution Of Hbv/hcv Coinfectiontherapy:-mentioning

confidence: 99%

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

AlZahrani¹

2017

IJAR

View full text Add to dashboard Cite

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Cited by 192 publications

References 36 publications

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

Treatment Uptake of Patients with Chronic Hepatitis C: Can We Expect and Do More?

Coinfection With Hepatitis B and Hepatitis C Virus: New Insights of Treatment in the Era of Direct Acting Antivirals.

Contact Info

Product

Resources

About